SLC40A1 and hemochromatosis type 1: Limiting the availability of iron for erythropoiesis through ferroportin inhibition might be a possible treatment approach for patients with β-NTDT, as well as those with other conditions associated with ineffective erythropoiesis or iron overload such as sickle cell disease, polycythemia vera, and hemochromatosis.